Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have earned an average recommendation of “Buy” from the fifteen ratings firms that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $38.31.

Several equities analysts have recently weighed in on ESPR shares. Citigroup Inc. raised their price target on Esperion Therapeutics to $77.00 in a report on Tuesday, March 21st. J P Morgan Chase & Co raised their price target on Esperion Therapeutics from $22.00 to $50.00 in a report on Tuesday, March 21st. Needham & Company LLC set a $25.00 price target on Esperion Therapeutics and gave the company a “buy” rating in a report on Saturday, March 18th. Deutsche Bank AG started coverage on Esperion Therapeutics in a report on Friday, June 23rd. They set a “buy” rating and a $48.00 price target for the company. Finally, BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, June 25th.

Several large investors have recently added to or reduced their stakes in ESPR. BB Biotech AG boosted its stake in Esperion Therapeutics by 7.6% in the first quarter. BB Biotech AG now owns 1,408,542 shares of the biopharmaceutical company’s stock valued at $49,736,000 after buying an additional 100,000 shares during the period. FMR LLC boosted its stake in Esperion Therapeutics by 70.8% in the first quarter. FMR LLC now owns 1,308,588 shares of the biopharmaceutical company’s stock valued at $46,206,000 after buying an additional 542,579 shares during the period. Boxer Capital LLC acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $45,020,000. Credit Suisse AG boosted its stake in Esperion Therapeutics by 26.4% in the first quarter. Credit Suisse AG now owns 878,824 shares of the biopharmaceutical company’s stock valued at $31,030,000 after buying an additional 183,440 shares during the period. Finally, Pinnacle Associates Ltd. boosted its stake in Esperion Therapeutics by 561.6% in the first quarter. Pinnacle Associates Ltd. now owns 770,618 shares of the biopharmaceutical company’s stock valued at $27,211,000 after buying an additional 654,138 shares during the period. 81.45% of the stock is currently owned by institutional investors.

Esperion Therapeutics (NASDAQ:ESPR) traded up 0.39% during trading on Tuesday, reaching $46.61. 462,880 shares of the company’s stock were exchanged. The stock’s market cap is $1.05 billion. The firm has a 50 day moving average of $36.52 and a 200-day moving average of $28.03. Esperion Therapeutics has a 12 month low of $9.40 and a 12 month high of $49.69.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Monday, May 1st. The biopharmaceutical company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.44) by $0.36. During the same quarter in the previous year, the company posted ($0.65) earnings per share. On average, equities research analysts anticipate that Esperion Therapeutics will post ($6.78) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Buy” from Brokerages” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/07/11/esperion-therapeutics-inc-nasdaqespr-receives-consensus-rating-of-buy-from-brokerages.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.